normative
Hard Clinical Endpoints Must Prove CGM Value to Payers
To justify a low-cost product to insurers, Dexcom needs hard endpoints such as fewer hospitalizations and surgeries, and savings from reducing unnecessary drugs, since a CGM can reveal that a GLP-1 is ineffective and a cheaper drug is warranted.
normativepending
Speaker
AnealEvidence Quote
“A CGM will tell you if, for example, your GLP-1 is not particularly effective and you need to come off that drug”
Created: 11/20/2026, 5:18:27 AM
Your notes
Loading notes...